Learning hub

The iPROLEPSIS project is where psoriatic arthritis inflammation is explained through multi-source data analysis guiding a novel personalized digital care ecosystem. Το iPROLEPSIS είναι μία λύση για την ψωριασική αρθρίτιδα Το έργο iPROLEPSIS είναι το σημείο αναφοράς για την κατανόηση της αντίδρασης της φλεγμονής στην ψωριασικής αρθρίτιδας μέσω της ανάλυσης δεδομένων πολλαπλών πηγών με χρήση ένος καινοτόμου εξατομικευμένου ψηφιακού οικοσύστηματος ιατρικής φροντίδας. ΠΕΡΙ ΤΗΣ ΚΟΙΝΟΠΡΑΞΙΑΣ ΕΠΙΚΟΙΝΩΝΗΣΤΕ ΜΑΖΙ ΜΑΣ ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Επερχόμενα γεγονότα Η ψωριασική αρθρίτιδα (ΨΑ) είναι μια χρόνια προοδευτική φλεγμονώδης ασθένεια που επηρεάζει 1-2% του γενικού πληθυσμού, ενώ εκδηλώνεται σε έως και 30% των ατόμων με ψωρίαση. Όραμα του έργου και αντίκτυπος Το iPROLEPSIS είναι ένα έργο που χρηματοδοτείται από το πλαίσιο Horizon Europe και αναπτύσσει ένα νέο εξατομικευμένο ψηφιακό οικοσύστημα φροντίδας για άτομα με ΨΑ. Ο στόχοςτης iPROLEPSIS είναι να προτείνει ένα νέο οικοσύστημα που περιλαμβάνει μηχανισμούς συλλογής δεδομένων πραγματικού κόσμου (RWD) και ένα ισχυρό σύστημα υποστήριξης αποφάσεων για την παροχή νέας γνώσης για τους βασικούς παράγοντες που επηρεάζουν τη μετάβαση από την υγεία σε ΨΑ, υιοθετώντας μια πολλαπλής κλίμακας/πολυπαραγοντική προσέγγιση, σε συνδυασμό πρακτικών επεξηγηματικής τεχνητής νοημοσύνης (explainable AI, xAI), να προσφέρει ένα αποτελεσματικό, αποδοτικό και κλινικά επικυρωμένο εξατομικευμένο ψηφιακό οικοσύστημα φροντίδας για ασθενείς με ΨΑ. ΑΝΑΚΑΛΥΨΕ ΠΕΡΙΣΣΟΤΕΡΑ Στόχοι του έργου και πακέτα εργασίας Η κοινοπραξία iPROLEPSIS εργάζεται πάνω σε 7 φιλόδοξους βασικούς στόχους στον τομέα της Ψωριασικής Αρθρίτιδας (ΨΑ) και έχει 6 πακέτα εργασίας στα οποία θα συγκεντρωθεί ποικίλη και συμπληρωματική τεχνογνωσία από τους εταίρους της κοινοπραξίας. ΑΝΑΚΑΛΥΨΕ ΠΕΡΙΣΣΟΤΕΡΑ Σχετικά με έ ργο 15 Συνεργάτες 9 Χώρες 48 Μήνες Διάρκεια έργου € 6,4 Εκατ. Συνολικός προϋπολογισμός Οι βασικοί τομείς δραστηριότητας Θεμελίωση • Τα θεμέλια για τις ερευνητικές δραστηριότητες του έργου τίθενται μέσω μιας εκτεταμένης διερεύνησης της διαθέσιμης βιβλιογραφίας και δεδομένων και του σχεδιασμού των μελετών συλλογής κλινικών δεδομένων και επικύρωσης. • Θα χρησιμοποιηθεί συμμετοχικός σχεδιασμός που υποστηρίζει την ανάπτυξη ενός οικοσυστήματος λύσεων προσανατολισμένου στους χρήστες για τη δημιουργία ενός πλαισίου για αξιόπιστη Ε&Α βασισμένη σε τεχνητή νοημοσύνη. Επικύρωση • Ο σχεδιασμός και η εφαρμογή των κλινικών μελετών κατά τις οποίες θα συλλεχθούν ερευνητικά δεδομένα, θα επικυρωθούν οι ψηφιακούς βιοδείκτες των φλεγμονωδών συμπτωμάτων σε άτομα που διατρέχουν κίνδυνο εκδήλωσης ψωριασικής αρθρίτιδας και ψωρίασης και θα αξιολογηθεί η αποτελεσματικότητα των εργαλείων ψηφιακής φροντίδας σε σχέση με την πρόβλεψη της έξαρσης της φλεγμονής. Ερευνα και ανάπτυξη • Έρευνα στην ανάλυση πολυτροπικών δεδομένων για την αποκάλυψη βασικών παραγόντων φλεγμονής της ΨΑ, την δημιουργία ψηφιακών βιοδεικτών των φλεγμονωδών συμπτωμάτων της ΨΑ και τη διερεύνηση της επίδρασης της ΨΑ στις αρθρώσεις και τη μικροαγγείωση του δέρματος, καθώς και τον ρόλο των μαστοκυττάρων στην εκδήλωση της ΨΑ. • Σύνθεση των αποτελέσματων σε ένα πολλαπλής κλίμακας/πολυπαραγοντικό μοντέλο για την πρόβλεψη μετάβασης από υγιή κατάσταση σε ΨΑ. • Παράδοση του ολοκληρωμένου ψηφιακού οικοσυστήματος υγείας iPROLEPSIS που περιλαμβάνει εργαλεία εξατομικευμένης προληπτικής φροντίδας της ΨΑ, για την υποστήριξη των ασθενών και των επαγγελματιών υγείας. Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Handbook Handbook 2 Psoriatic Arthritis Key Facts Key Facts Psoriatic Arthritis Handbook Handbook Quizzes about Psoriatic Arthritis Take a Quiz Project news Handbook Handbook 2 iPROLEPSIS Newsletter No. 11 Read More AI-Driven Early Prediction and Personalised Care | iPROLEPSIS, AI-PROGNOSIS & REBECCA Read More Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Read More ΑΝΑΚΑΛΥΨΕ ΠΕΡΙΣΣΟΤΕΡΑ Επικοινώνησε μαζί μας Σχόλια ή ερωτήσεις σχετικά με το έργο iPROLEPSIS είναι ευπρόσδεκτα! ΕΠΙΚΟΙΝΩΝΗΣΤΕ ΜΑΖΙ ΜΑΣ

Σχετικά με τα μέλη της κοινοπραξίας Dr. Ioannis Drivas DIADIKASIA BUSINESS CONSULTING SYMVOULOI EPICHEIRISEON AE (DBC) Position Principal researcher focusing on the development of digital biomarkers and their translation into healthcare tools and interventions. What is your role in iPROLEPSIS? Project Manager What are your main activities in the project? As Project Manager, I coordinate all iPROLEPSIS-related activities assigned to DBC. What is your motivation? My motivation stems from a strong commitment to upholding ethical and legal standards in research while maximizing the impact and real-world use of the iPROLEPSIS results. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication

Learning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Living with Psoriatic Arthritis Handbook How will psoriatic arthritis affect me? WORK Work can provide a sense of purpose, identity, achievement, and a supportive social network, contributing positively to your emotional and physical wellbeing. While your condition may pose some challenges, people living with psoriatic arthritis can continue to work as long as their profession does not exacerbate their symptoms and worsen their health. People with certain health conditions have defined rights set out in law, designed to protect them against direct and indirect discrimination in the workplace. Your employer is legally obligated to make “reasonable accommodations” to your working environment and practices to ensure your condition does not prevent you from doing your job to the best of your ability and in a comfortable and safe environment. h3.1 In the European Union, the definition of reasonable accommodation at work was introduced by Article 5 of the Employment Equality Directive (Directive 2000/28/EC): “shall take appropriate measures, where needed in a particular case, to enable a person with disability to have access to, participate in, or advance in employment, or to undergo training, unless such measures would impose a disproportionate burden on the employer.” This directive has been transposed into national law in all EU member states. Research has shown that people who need workplace accommodations and effectively use them are more likely to keep a job and stay productive than those who do not use workplace accommodations (39). However, asking for workplace accommodations can be difficult. You may be concerned about being treated differently and negative reactions from your supervisor(s) or colleague(s). For this reason, you may prefer to negotiate informal workplace accommodations rather than seeking formal accommodations. Some of these accommodations may include those supported by the American College of Sports Medicine guidelines for physical activity and public health (40) and the ISO 11226 standard , https://www. iso.org/standard/25573.html , which defines joint limits to safeguard musculoskeletal health. By aligning workplace practices with these scientifically supported guidelines, employers and healthcare professionals can better accommodate the needs of their employees, fostering an inclusive and supportive work environment. Some examples follow: Recommendation #1: Avoid working for prolonged periods in the same position, whether sitting or standing. During the work shift: a continuous period of time in the standing position should not exceed 1 hour; the total time spent in a standing position should not exceed 4 hours; continuous sitting should be limited to 2 hours; when periods are dedicated to holding meetings, the duration of which should be reasonable, consideration should be given to the possibility of having them while standing or walking (41). Recommendation #2: Take frequent breaks throughout the shift. Please note that he definition of “breaks” must consider the following characteristics: Frequency: number of breaks/interruptions during the working day; Duration: micro-breaks (less than 2 minutes); short breaks (typically those that occur in the morning or afternoon, lasting between 7 and 10 minutes); or long breaks (meal breaks); and Type: passive or resting and active (including stretching or walking) (42). Thus, in an 8-hour working day, a worker should take at least a 7–10-minute break after consecutive 90-minute work periods. Recovery periods can include moments of rest or the performance of any other task to recover the muscle groups that have been worked. Within a period of at least 90 minutes, a worker should enjoy at least 30 seconds after 20 minutes of work. Both recommendations aim to address the prolonged exposure to low-intensity static load by limiting the duration of this exposure. These interventions help to alleviate fatigue and pain symptoms in the short-term, and to prevent work-related musculoskeletal injuries in the long-term. Active breaks add value; however, they do not replace the need to introduce diversity in the intensity of the mechanical load, such as rotational planes suited to the job’s demands (43). Please note that these recommendations refer to low-intensity, physically demanding tasks. Other recommendations apply to high-intensity tasks, such as those involving manual force. Recommendation #3: Physical changes to workstations work surfaces (desks) that allow alternation between standing and sitting, alone or combined with a training and information program for workers, reduce sitting time by approximately 60 minutes per working day (in the medium term, i.e., up to 3-12 months). This change in physical working conditions can bring about a behavioural change, with repercussions in an average reduction of 82 minutes in total sitting time per day (at and away from work) and in the average duration of consecutive periods of sitting (57 minutes) (42, 44). Even though workplace adaptations are consigned in the law, many people living with rheumatic and musculoskeletal diseases report a lack of understanding from their employer(s), colleague(s), and workplace doctor(s). You have options and rights; it is important to understand them and fully explore all available alternatives. If you are unsure about your rights in the workplace, please get in touch with your HR or occupational health department. More information can be found below: The Advisory, Conciliation and Arbitration Service. (ACAS) https://www.acas.org.uk/reasonable-adjustments If you require workplace adaptations, please talk to your assistant doctor about the difficulties you have been feeling and request reports to present to your employer and/or workplace doctor. See related Key Facts section SLEEP Pain, anxiety, and side effects of the medication can make it more difficult for a person with psoriatic arthritis to fall asleep and stay asleep throughout the night. In fact, about 40% of people living with psoriatic arthritis report sleep difficulties (45). Good sleep hygiene habits may help to improve sleep: develop a regular sleep routine, that is, go to bed and get up at a similar time each day; avoid caffeine, alcohol, and large meals before you go to bed; if you smoke, try to stop smoking, or at least do not smoke close to bedtime; a warm bath before bedtime may help ease pain and stiffness; listen to soothing music or sounds before going to bed; avoid watching TV and using computers, tablets, or smartphones in your bedroom; make sure your bedroom is dark, quiet, relaxing, and at a comfortable temperature. h3.2 The impact of exercising before bedtime can vary among individuals. It is essential to listen to your body, establish a consistent routine, and pay attention to how evening workouts affect your sleep patterns. If you have specific concerns about your sleep or exercise routine, it is also advisable to consult with a healthcare professional or a fitness expert. Pros: Improved sleep quality: For some people, engaging in moderate-intensity exercises a few hours before bedtime may promote better sleep quality. It can help reduce stress and anxiety, leading to a more relaxed state conducive to sleep. Body temperature regulation: Exercise increases body temperature, and the subsequent drop in temperature after exercise can signal the body that it is time to sleep. This mimics the natural temperature drop that occurs during the evening. Establishing a routine: Regular exercise, regardless of the time of day, can contribute to better sleep quality. Establishing a consistent exercise routine is often more important than the specific time of day. Cons: Stimulating effect: For some people, intense exercise close to bedtime may have a stimulating effect, making it more challenging to wind down and fall asleep. Body temperature: While the drop in body temperature after exercise can promote sleep, exercising too close to bedtime may disrupt the body’s natural cooling process, potentially interfering with sleep. Individual variability: People respond differently to exercise timing. Some may find that late-night workouts do not impact their sleep, while others may experience difficulties. Recommendations: Timing matters: Try to finish exercising at least 2-3 hours before bedtime to allow your body temperature to return to normal and your adrenaline levels to decrease. Listen to your body: Pay attention to how your body responds to evening workouts. It might be a good fit for you if it helps you relax and improves your sleep. Experiment: Everyone is different. Experiment with varying timings of exercise to see what works best for you. If evening workouts negatively impact your sleep, consider shifting them earlier. Moderation is key: Intense or vigorous exercise close to bedtime might be more likely to interfere with sleep. Opt for moderate-intensity activities in the evening (47). Nearly 50% of patients living with psoriatic arthritis report high levels of fatigue (five or higher on a 10-point scale) and consider fatigue a high-ranking problem, after joint pain and before skin issues (48). See related Key Facts section FATIGUE Problem solving, planning, prioritising, and pacing may help you cope better with your fatigue: PROBLEM SOLVING Identify factors / tasks / chores / activities that are contributing to your fatigue; Think about solutions that could help minimise the impact of these factors/tasks/chores/ activities. PLANNING Plan the tasks/chores/activities you want to complete in a day or week; Make sure to include activities that you enjoy and can improve your mood/wellbeing; Do not beat yourself up if you cannot stick to the plan. PRIORITISING Organise your tasks/chores/activities by order of importance. PACING Do not use your energy all in one go; Break the planned tasks/chores/activities into smaller portions that can be spread out over the course of a day, a week or even longer. See related Key Facts section EMOTIONAL WELLBEING Living with psoriatic arthritis can take a toll on your mental health (49, 50). You need to treat mental health symptoms as seriously as physical symptoms. Poor mental health can cause your psoriatic arthritis to flare, increase pain and fatigue, negatively affect your work and personal relationships, and limit your ability to manage your overall health. If you feel sad, hopeless, and lose interest in things you used to enjoy, talk to your doctor, and let your loved ones know what you are going through. Your doctor may redirect you to useful mental health services such as cognitive behavioural therapy (CBT) and/or they may prescribe you an antidepressant. h3.3 h3.4 Remember that you are not alone. If you need extra support, we are here to help you: NHS Mental Health Services https://www.nhs.uk/nhs-services/mental-health-services/ VERSUS ARTHRITIS / Psoriatic arthritis https://versusarthritis.org/ +44 800 520 0520 Be kind to your joints and your mind. See related Key Facts section See related Key Facts Previous page Next page

Download needed deliverables for iProlepsis project for psoriatic arthritis. Παραδοτέα D1.2 Data managmeent plan (initial version) WP1 - Management and coordination Read More D2.3 The iPROLEPSIS trustworthy AI framework WP2 - Knowledge mining, foundation and participatory design Read More D6.1 Project branding and communication channels WP6 - Dissemination, communication and exploitation Read More D2.1 Initial report on user research and co-creation process WP2 - Knowledge mining, foundation and participatory design Read More D4.2 The iPROLEPSIS patient and HCP apps (study version) WP4 - Development of the iPROLEPSIS digital health ecosystem for personalised preventive care Read More D6.2 Dissemination, exploitation and communication plan WP6 - Dissemination, communication and exploitation Read More D2.2 Initial report on the state-of-the-art and datasets WP2 - Knowledge mining, foundation and participatory design Read More D5.1 Study initiation package (iPROLEPSIS-PDPID study) WP5 - Clinical studies Read More D6.3 First report on project visibility and educational material WP6 - Dissemination, communication and exploitation Read More

iPROLEPSIS project will perform four different clinical studies in four different counties. Learn more about clinical studies by visiting iprolepsis.eu. Σχετικά με τις κλινικές μελέτες Στα πλαίσια του iPROLEPSIS τέσσερεις κλινικές μελέτες θα λάβουν χώρα. 1. iPROLEPSIS-PDPID Μελέτη ψηφιακού φαινότυπου και των παραγόντων φλεγμονής της ψωριασικής αρθρίτιδας. 2. iPROLEPSIS-MOJMI Μελέτη οπτοακουστικής απεικόνισης των αρθρώσεων και του μικροαγγειώματος. 3. iPROLEPSIS-IDBV Μελέτη επικύρωσης ψηφιακών βιοδεικτών φλεγμονής. 4. iPROLEPSIS-PPIDC Μελέτη παρέμβασης για την πρόληψη των συμπτωμάτων της ΨΑ. Οι κλινικές μελέτες θα πραγματοποιηθούν σε 5 χώρες: Ολλανδία Ηνωμένο Βασίλειο Πορτογαλία Ελλάδα Γερμανία Κλινικές μελέτες Μελέτη οδηγών ψηφιακού φαινοτύπου και φλεγμονής PsA (iPROLEPSIS-PDPID) Κοόρτη ανάπτυξης ψηφιακών βιοδεικτών βασισμένων σε smartphone και έξυπνα ρολόγια, με γνώμονα την τεχνητή νοημοσύνη για απομακρυσμένη αξιολόγηση και παρακολούθηση ατόμων με ψωριασική αρθρίτιδα. Μέτρηση Να αναπτύξουν νέους ψηφιακούς βιοδείκτες smartphone και έξυπνων συσκευών (ζώνη, δαχτυλίδι, κάμερα) για την αξιολόγηση φλεγμονωδών συμπτωμάτων με ιδιαίτερη έμφαση στην αναγνώριση αλλαγών στα μοτίβα κίνησης, πόνου, κόπωσης, πρωινής δυσκαμψίας σε σύγκριση με το χρυσό πρότυπο – ιατρική αξιολόγηση με κλινική αξιολόγηση των αρθρώσεων, των τενόντων και του δέρματος. Πρόβλεψη Για την πρόβλεψη της αλλαγής από μη φλεγμονώδες σε φλεγμονώδες, χρησιμοποιώντας τρεις ενεργοποιητές που μπορεί να προκαλέσουν μακροχρόνια φλεγμονή σε ασθενείς με ψωριασική αρθρίτιδα που διατρέχουν κίνδυνο έξαρσης. Αυτοί οι τρεις παράγοντες ενεργοποίησης είναι το στρες, το μηχανικό στρες και οι αλλαγές στο μικροβίωμα του εντέρου. ΣΤΟΧΟΙ Κύριοι στόχοι • για την παροχή ακριβών, τεκμηριωμένων και κλινικά συναφών αρχείων του αυτόνομου smartphone και smartwatch[1] που βασίζεται σε σύστημα ψηφιακού βιοδείκτη που βασίζεται σε AI για την ανίχνευση φλεγμονής ειδικής PsA. • για την πρόβλεψη ακριβούς, τεκμηριωμένης και κλινικά σχετικής φλεγμονής για το PsA. Δευτερεύοντες στόχοι • για τον προσδιορισμό της αξιοπιστίας μεταξύ ατόμων του συστήματος ψηφιακών βιοδεικτών που βασίζεται στην τεχνητή νοημοσύνη, • για τον προσδιορισμό της εγκυρότητας της δομής έναντι της κλινικής αξιολόγησης της φλεγμονής. • για τον προσδιορισμό της εγκυρότητας της δομής έναντι της αξιολόγησης της φλεγμονής από τον ασθενή. • για τον προσδιορισμό κλινικά σχετικών αλλαγών στο σύστημα ψηφιακού βιοδείκτη που βασίζεται στην τεχνητή νοημοσύνη. • για τον προσδιορισμό της ελάχιστης ανιχνεύσιμης διαφοράς στο σύστημα ψηφιακού βιοδείκτη που βασίζεται σε AI, • για την αξιολόγηση της διακύμανσης του στρες μεταξύ των ατόμων, του μηχανικού στρες και των αλλαγών στο μικροβίωμα του εντέρου σχετικά με την εμφάνιση φλεγμονής. • για την αξιολόγηση της συμμόρφωσης και της ικανοποίησης των χρηστών με το ψηφιακό σύστημα παρακολούθησης που βασίζεται σε smartphone και smartwatch, βασισμένο σε AI[1]. Η μελέτη έχει σχεδιαστεί για να αναπτύξει έναν νέο τρόπο μέτρησης της φλεγμονής σε ασθενή με ψωριασική αρθρίτιδα. Ορισμός νέων οπτοακουστικών βιοδεικτών της ψωρίασης και της ψωριασικής αρθρίτιδας (iPROLEPSIS-MOJMI) Αυτή η μελέτη συνδυάζει τα ευρήματα των πρόσφατα αναπτυγμένων ψηφιακών βιοδεικτών, τα πρώιμα ευρήματα των ενεργειών: στρες, μηχανικό στρες και αλλαγές στο μικροβίωμα από τη μελέτη ψηφιακού φαινοτύπου PsA και οδηγών φλεγμονής (iPROLEPSIS-PDPID), για να παρέχει μια εξατομικευμένη προσέγγιση αντιμετωπίστε τα ερεθίσματα με σύγχρονες παρεμβάσεις. ΣΤΟΧΟΙ Κύριοι στόχοι Σε ασθενείς με PsA με χαμηλή δραστηριότητα της νόσου, μια εξατομικευμένη παρέμβαση στο φαγητό, τη σωματική δραστηριότητα και το στρες που βασίζεται σε ένα προσωπικό προφίλ άγχους, μηχανικού στρες και μικροβιώματος θα συγκριθεί με τη συνήθη φροντίδα για την ανάπτυξη φλεγμονής όπως ανιχνεύεται από το πρόσφατα αναπτυγμένο σύστημα ψηφιακού βιοδείκτη και κλινική εξέταση. Δευτερεύοντες στόχοι • να αξιολογήσει την αποδοχή και την αποδοχή του ψηφιακού βιοδείκτη και της παρέμβασης ως μέρος της συνήθους ιατρικής θεραπείας μεταξύ ασθενών, γιατρών και νοσηλευτών. • για αξιολόγηση της συμμόρφωσης με την εξατομικευμένη παρέμβαση. Μελέτη επικύρωσης ψηφιακών βιοδεικτών φλεγμονής (iPROLEPSIS-IDBV) Κοόρτη ανάπτυξης ψηφιακών βιοδεικτών βασισμένων σε smartphone και έξυπνα ρολόγια, με γνώμονα την τεχνητή νοημοσύνη για απομακρυσμένη αξιολόγηση και παρακολούθηση ατόμων με ψωριασική αρθρίτιδα. Μέτρηση Να αναπτύξουν νέους ψηφιακούς βιοδείκτες smartphone και έξυπνων συσκευών (ζώνη, δαχτυλίδι, κάμερα) για την αξιολόγηση φλεγμονωδών συμπτωμάτων με ιδιαίτερη έμφαση στην αναγνώριση αλλαγών στα μοτίβα κίνησης, πόνου, κόπωσης, πρωινής δυσκαμψίας σε σύγκριση με το χρυσό πρότυπο – ιατρική αξιολόγηση με κλινική αξιολόγηση των αρθρώσεων, των τενόντων και του δέρματος. Πρόβλεψη Για την πρόβλεψη της αλλαγής από μη φλεγμονώδες σε φλεγμονώδες, χρησιμοποιώντας τρεις ενεργοποιητές που μπορεί να προκαλέσουν μακροχρόνια φλεγμονή σε ασθενείς με ψωριασική αρθρίτιδα που διατρέχουν κίνδυνο έξαρσης. Αυτοί οι τρεις παράγοντες ενεργοποίησης είναι το στρες, το μηχανικό στρες και οι αλλαγές στο μικροβίωμα του εντέρου. ΣΤΟΧΟΙ Κύριοι στόχοι • για την παροχή ακριβών, τεκμηριωμένων και κλινικά συναφών αρχείων του αυτόνομου smartphone και smartwatch[1] που βασίζεται σε σύστημα ψηφιακού βιοδείκτη που βασίζεται σε AI για την ανίχνευση φλεγμονής ειδικής PsA. • για την πρόβλεψη ακριβούς, τεκμηριωμένης και κλινικά σχετικής φλεγμονής για το PsA. Δευτερεύοντες στόχοι • για τον προσδιορισμό της αξιοπιστίας μεταξύ ατόμων του συστήματος ψηφιακών βιοδεικτών που βασίζεται στην τεχνητή νοημοσύνη, • για τον προσδιορισμό της εγκυρότητας της δομής έναντι της κλινικής αξιολόγησης της φλεγμονής. • για τον προσδιορισμό της εγκυρότητας της δομής έναντι της αξιολόγησης της φλεγμονής από τον ασθενή. • για τον προσδιορισμό κλινικά σχετικών αλλαγών στο σύστημα ψηφιακού βιοδείκτη που βασίζεται στην τεχνητή νοημοσύνη. • για τον προσδιορισμό της ελάχιστης ανιχνεύσιμης διαφοράς στο σύστημα ψηφιακού βιοδείκτη που βασίζεται σε AI, • για την αξιολόγηση της διακύμανσης του στρες μεταξύ των ατόμων, του μηχανικού στρες και των αλλαγών στο μικροβίωμα του εντέρου σχετικά με την εμφάνιση φλεγμονής. • για την αξιολόγηση της συμμόρφωσης και της ικανοποίησης των χρηστών με το ψηφιακό σύστημα παρακολούθησης που βασίζεται σε smartphone και smartwatch, βασισμένο σε AI[1]. Η μελέτη έχει σχεδιαστεί για να αναπτύξει έναν νέο τρόπο μέτρησης της φλεγμονής σε ασθενή με ψωριασική αρθρίτιδα. Πρόληψη της φλεγμονής του PsA μέσω της ψηφιακής φροντίδας: μια μελέτη παρέμβασης (iPROLEPSIS-PPIDC) Αυτή η μελέτη συνδυάζει τα ευρήματα των πρόσφατα αναπτυγμένων ψηφιακών βιοδεικτών, τα πρώιμα ευρήματα των ενεργειών: στρες, μηχανικό στρες και αλλαγές στο μικροβίωμα από τη μελέτη ψηφιακού φαινοτύπου PsA και οδηγών φλεγμονής (iPROLEPSIS-PDPID), για να παρέχει μια εξατομικευμένη προσέγγιση αντιμετωπίστε τα ερεθίσματα με σύγχρονες παρεμβάσεις. ΣΤΟΧΟΙ Κύριοι στόχοι Σε ασθενείς με PsA με χαμηλή δραστηριότητα της νόσου, μια εξατομικευμένη παρέμβαση στο φαγητό, τη σωματική δραστηριότητα και το στρες που βασίζεται σε ένα προσωπικό προφίλ άγχους, μηχανικού στρες και μικροβιώματος θα συγκριθεί με τη συνήθη φροντίδα για την ανάπτυξη φλεγμονής όπως ανιχνεύεται από το πρόσφατα αναπτυγμένο σύστημα ψηφιακού βιοδείκτη και κλινική εξέταση. Δευτερεύοντες στόχοι • να αξιολογήσει την αποδοχή και την αποδοχή του ψηφιακού βιοδείκτη και της παρέμβασης ως μέρος της συνήθους ιατρικής θεραπείας μεταξύ ασθενών, γιατρών και νοσηλευτών. • για αξιολόγηση της συμμόρφωσης με την εξατομικευμένη παρέμβαση.

Learning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts Key Facts Quizzes about Psoriatic Arthritis Take a Quiz Search about Psoriatic Arthritis Search Psoriatic Arthritis Handbook Handbook News Feed about Psoriatic Arthritis News Feed

iPROLEPSIS networking activities Our shared vision is to establish a robust ecosystem of initiatives , where the combined strength of each project contributes to the overarching goal of advancing healthcare and well-being . By pooling our resources, knowledge, and expertise, we believe in the potential for significant benefits both for the collaborative cluster and the individual projects involved. Networking projects funded under the call HORIZON-HLTH-2022-STAYHLTH-02-01 CARE-IN-HEALTH Cardiovascular REsolution of INflammation to promote HEALTH WEBSITE Cardiovascular diseases (CVD) are the leading cause of mortality in Europe (1.9 million of annual deaths). CVD are significant public health challenge, accounting for €200 billion in economic burden annually in Europe. Lipid-mediated chronic inflammation and particularly the failure in the resolution of the inflammation, is a particular critical risk factor for the transition from health to CVD. CARE-IN-HEALTH addresses this by aiming to identify the pathways involved in the resolution of the lipid-mediated inflammation to prevent and reverse inflammation and therefore CVD. The interdisciplinary consortium will collect and integrate epidemiological, multi-omics, and immune data to create the CARE-IN-HEALTH Atlas, which will be openly accessible to the scientific community. Such a knowledge base will allow to systematically identify and validate individual’s critical immune pathways. A CARE-IN-HEALTH MCDSS (multi-criteria decision support system) will guide healthcare professionals to design personalised CVD prevention strategies. The CARE-IN-HEALTH BIOSENSOR will monitor inflammation resolution for citizens. CARE-IN-HEALTH will demonstrate proof-of-concept for an appropriate lipid intake as dietary intervention and specifically, for the use of vegetal omega-3 fatty acid sources as substrates for immunomodulatory lipid mediators and resolution of inflammation. All this is based on the results of a proof-of-concept clinical trial. GlycanTrigger Glycans as master triggers of health to intestinal inflammation transition WEBSITE GLYCANTRIGGER - Glycans as master triggers of health to intestinal inflammation transition. The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with Crohn’s Disease that will be translated into improved disease prediction and prevention. The project will address how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms but also systemic mechanisms, involving the novel concept of glycan mimicry as an early trigger of the health-to-inflammation transition. The long-term goal of this project is to unlock a new checkpoint that regulates the transition to chronic inflammation, aiming to figure out how to turn off this process by developing novel preventive intervention strategies. halt-RONIN Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies. Downolad PDF to read more. WEBSITE NAFL (non-alcoholic fatty liver) is the most widespread subtype of NAFLD, a highly prevalent inflammation-related disease, characterized by steatosis, relatively benign and reversible condition, which can progress to the more serious progressive stage of non-alcoholic steatohepatitis (NASH), in which steatosis is accompained by lipotoxicity, mitochondrial dysfunction and a high state of inflammation and fibrosis. IMMEDIATE Imminent Disease Prediction and Prevention at the Environment Host Interface WEBSITE The EU-funded research project IMMEDIATE strives to identify individual biomarkers of risk and resilience against chronic inflammation by investigating the diet-microbiome-metabolite-immune axis. This complex interaction refers to how an individual's diet, gut microbiota, metabolites, and immune system can influence their health. IMMEDIATE will use cutting-edge technologies and clinical and metadata from large observational cohort studies to identify pre-disease stages and further our understanding of the mechanisms and molecular pathways underpinning non-communicable diseases. Furthermore, a proof-of-concept study on healthcare professionals will be conducted to test the effectiveness of a probiotic intervention and ultimately develop mobile apps designed to offer personalized lifestyle recommendations and empower citizens to manage their own health proactively. INITIALISE Inflammation in human early life: targeting impacts on life-course health WEBSITE INITIALISE (Inflammation in human early life: targeting impacts on life-course health) is an EU funded project that aims to elucidate how exposures and genome impact gut microbiome, host immune system and metabolism, and how the interplay of these factors impact life-course health.  INITIALISE aims to define the role of the maturation of the immune system as a mediator between exposures and life-course health. INTERCEPT-T2D Early Interception of Inflammatory-mediated Type 2 Diabetes WEBSITE Inflammatory-based interceptive medicine in type 2 diabetes Individuals with type 2 diabetes (T2D) do not use insulin efficiently and, therefore, their glucose levels rise. T2D is a heterogeneous disease, which is an obstacle to the delivery of an optimal tailored treatment. Consequently, patients’ individual trajectories of progressive hyperglycaemia and risk of chronic complications such as stroke, heart attacks, nephropathy and retinopathy are so far difficult to predict. Chronic systemic inflammation has been suggested to be a major contributor to the onset and progression of T2D complications. The EU-funded INTERCEPT-T2D project will bring a new and clinically relevant dimension in T2D care considering at diagnosis inflammatory parameters that are of importance for the transition to T2D-related complications. Moreover, the project will help deliver optimal treatments tailored to patient needs and conduct a clinical trial to evaluate the efficacy of anti-inflammatory strategies. miGut-Health Personalised blueprint intestinal health WEBSITE The miGut-Health project is an EU-funded initiative that is developing novel strategies to predict and prevent inflammatory bowel disease (IBD). miGut-Health aims to create personalised patient engagement strategies for predicting and monitoring preclinical IBD by focusing on the transitory phase from health to disease. The overarching goal is to provide strategies for early disease prediction, prevention and gut health improvement for people affected by IBD, high-risk individuals and citizens. AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation WEBSITE Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook. Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a ‘risk score’ for gastric cancer and shed light on the mechanisms of its evolution. Aida aims to do just that. It helps researchers understand the mechanisms that trigger gastric oncogenesis, helps clinicians diagnose precancerous inflammation at the earliest possible stage, suggests personalised therapeutic strategies for treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. This places Aida squarely on Europe’s agenda of ‘Staying healthy in a rapidly changing society’. Aida unites some of Europe’s leading authorities in the field of gastric inflammation, gastric cancer, leading AI and machine learning experts, experts on data governance and privacy, representatives of the public administration and patient advocates. Aida also has strong ties with the industry. After the project, the results will live on in a foundation that acts as a transnational focal point for chronic gastric inflammation — and GC in general. We hope that the solid, inclusive design principles of Aida, its societal relevance and its durability will spawn a vigorous ecosystem around chronic gastric inflammation, its understanding and its treatment. And we hope that it will inspire other data collaboratives in health — for other chronic inflammations, other forms of cancer or other ailments altogether. PROTO Advanced Personalized Therapies for Osteoarthritis WEBSITE Osteoarthritis (OA) is a chronic progressive joint disorder, characterized by inflammation causing pain, stiffness, swelling and gradual loss of joint function. PROTO aims to halt and partially reverse the structural and functional changes caused by inflammatory processes in OA Our ambitious goal is to introduce: a highly innovative anti-inflammatory local placental derived cell therapy in early-stage OA patients and a personalized sensor-based training intervention intended to prevent inflammation and OA onset during a crucially important ‘window of opportunity’ by correcting pathological movement patterns in pre-stage OA patients. ENDOTARGET Sytemic Endotoxemia as the driver of chronic inflammation–Biomarkers and novel therapeutic targets for Arthritis WEBSITE ENDOTARGET explores the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints. Based on the gained knowledge, e.g. new biomarkers for risk assessment will be identified and a Rheumatic disease risk prediction tool (RDPT) will be developed to support clinicians in the classification of patients and to treat RDs preventively. This tool will help to reduce the risk of RD onset and/or to reduce disease activity. PRAESIIDIUM Real-time prediction of the prediabetes risk WEBSITE PRAESIIDIUM will develop a tool based on artificial intelligence coupled with multi-scale, multi-organ integrated mathematical equations for the real-time prediction of the prediabetes risk of an individual. The prediction algorithm will draw on a rich set of information for training, derived from prior clinical data, the individual’s family history, and a pilot study testing wearable sensors that will provide glucose, bioimpedance, and heart rate monitoring. The PRAESIIDIUM platform will be made available to healthcare professionals and patients for an easier data entering and results query and it will be linked to common wearable sensors to monitor the physical activity. PREVALUNG EU Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception WEBSITE The project PREVALUNG EU will harness retrospective and prospective cohorts of both CVD patients and LCDT eligibles to develop actionable biomarkers and validate the four classifiers detecting high-risk individuals before or pre-symptomatic of LC, exploiting the latest advances of system biology omics (metabolomics, metagenomics, immunomics, proteomics, and aging-associated BM stem cell genomics) that correlate with uncontrolled inflammatory status of CVD patients. In particular, using four types of diagnosis tools harnessing either of the four drivers of overt inflammation (metabolism, gut dysbiosis, stem cell mutational status, innate immunity), we shall stratify the CVD patient population and leverage the PLCOm2012 risk score to better identify LC high-risk individuals. We will propose a personalized interceptive measure, whose efficacy will be monitored using PREVALUNG EU Focus Panels. We will robustly validate clinical applications, workflows, and tools for easy and broad adoption of the interceptive system across European public care centers and private stakeholders.

Learning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Key Facts keyfacts 1 Understanding Psoriatic Arthritis Learn what psoriatic arthritis is, how it’s connected to psoriasis, what symptoms to look out for, how it’s diagnosed, and how to recognise a flare. f1.1 f1.2 See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f1.3 f1.5 F1.4 keyfacts 2 Managing Psoriatic Arthritis: Treatments and Lifestyle Learn how psoriatic arthritis is treated through medications, non-pharmacological treatments, and everyday lifestyle choices that support health and wellbeing. See related Handbook section See related Handbook section See related Handbook section See related Handbook section See related Handbook section f2.1 f2.2 f2.3 f2.4 f2.5 keyfacts 3 Living with Psoriatic Arthritis Everyday tips for balancing work, improving sleep, managing fatigue, and supporting mental wellbeing. f3.1 See related Handbook section See related Handbook section See related Handbook section See related Handbook section f3.2 f3.3 f3.4 key facts 4 Intimacy, Reproductive Health and Family Life Understanding how psoriatic arthritis may affect relationships, sexual and reproductive health, and family planning decisions. See related Handbook section See related Handbook section See related Handbook section See related Handbook section f4.1 f4.2 f4.3 f4.4

Learning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Intimacy, Reproductive Health and Family Life Handbook How will psoriatic arthritis affect me? RELATIONSHIPS AND SEX Psoriatic arthritis can present a number of challenges in a relationship, namely: reduce your enjoyment of sex and other activities you share with your partner; affect your mood and self-esteem; impact your ability to contribute to household and family related duties; lead to financial worries if your condition affects your ability to work. Although your relationship may change because of psoriatic arthritis, you should remember that most couples go through phases in their relationship that are more or less positive, depending on a number of factors such as stress, work-life balance, or other health conditions. See related Key Facts section h4.1 h4.3 Talking to your partner about any changes or challenges you may be facing is a great way to improve communication in the relationship and arrive at solutions to please both of you. If you are not in a relationship and worry about how your condition may affect your prospects of finding a romantic partner, especially if you have visible signs of the condition, keep in mind that most relationships develop gradually and that shared interests are more important than physical considerations. While sex will not make your psoriatic arthritis worse, it can sometimes be painful when you move an affected joint. Besides the physical aspect, psoriatic arthritis may decrease your sex drive, affect your self- confidence, or make you feel less attractive. Psoriatic arthritis can sometimes lead to a dry vagina, and thus to uncomfortable sex. If this is the case, water-based lubricants can help you and/or your partner. Oil-based lubricants may irritate your skin or damage condoms. To help you overcome difficulties with sex, you should: talk openly with your partner about your physical and/or emotional concerns; keep active as physical exercise can help you strengthen your muscles and support your joints; take painkillers approximately one hour before having sex to minimise pain; try different positions and use cushions, pillows, or furniture to support your body; remember that there are multiple ways to achieve sexual satisfactions, such as kissing, caressing, mutual masturbation, oral stimulation, or even sex aids such as vibrators. See related Key Facts section FERTILITY, PREGNANCY, AND BREASTFEEDING If you are planning to start a family, you should discuss your treatment plan with your rheumatologist, as some medications are not safe in pregnancy. It is completely normal to feel concerned about the effect of your condition on your ability to start a family. People with arthritis may take slightly longer to become pregnant. It is best to try for a baby when your condition is not very active. There is a genetic contribution to psoriatic arthritis, that is, the presence of certain genes makes a person more likely to develop the condition. However, this is not a strictly hereditary condition. There are many factors involved in the development of psoriatic arthritis, not just the genes inherited from parents. Therefore, in the vast majority of cases the chances of passing it on to your children are relatively low. FERTILITY In women, there is no evidence to support that psoriatic arthritis affects fertility (51). However, a recent study indicated that untreated inflammatory arthritis, such as psoriatic arthritis, may decrease male fertility (52). In both women and men, fertility does decrease with age or may be affected by other health conditions. h4.2 Therefore, some people living with psoriatic arthritis will need fertility treatments. If your psoriatic arthritis is under control, there should be no problem to initiate fertility treatments. Discuss any plans for fertility treatments with your rheumatologist. They can offer specific advice, review your treatment plan, and liaise with the medical team responsible for your fertility treatment. See related Key Facts section PREGNANCY AND BREASTFEEDING Discuss your plans to start a family with your rheumatologist so that your treatment plan can be adjusted. If you become pregnant unexpectedly, talk to your rheumatologist as soon as possible. All women get aches and pains during pregnancy. As the baby grows, you may feel additional strain on some of your joints, especially on your hips and knees. While there is not a lot of information on the effects of pregnancy in psoriatic arthritis, studies have shown that the majority of women living with rheumatoid arthritis experience some form of symptom improvement during pregnancy. However, some women will have a flare after giving birth. Psoriatic arthritis usually does not affect delivery and you can still give birth through your vagina. If you are considering a caesarean, you should discuss this with your doctors (rheumatologist and obstetrician). It may be necessary to stop some of your medications before the surgery. You should continue anti-rheumatic drugs that are safe in pregnancy during pregnancy and breastfeeding. This will reduce your chances of any complications during pregnancy and will make flares less likely after giving birth. Many mothers feel sad, tearful, or anxious in the first two weeks after having a baby. However, if these symptoms last for longer or start later on, you may have post-natal depression, which affects 1 in 10 women after giving birth. It is important to seek medical help if you feel this way. See related Key Facts section h4.4 Remember that you are not alone. If you need extra support, please speak to your GP or Health Visitor. More information can be found below: NHS Mental Health Services https://www.nhs.uk/nhs-services/mental-health-services/ NHS Postnatal Depression https://www.nhs.uk/mental-health/ conditions/post-natal-depression/overview/ Be kind to your joints and your mind. See related Key Facts Previous page Next page

Leraning hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Psoriatic Arthritis Handbook Handbook Handbook Understanding Psoriatic Arthritis Handbook Sections What is psoriatic arthritis? What causes psoriatic arthritis? What are the symptoms of psoriatic arthritis? How is psoriatic arthritis diagnosed? Read Sections Living with Psoriatic Arthritis Handbook Sections Work Sleep and fatigue Emotional wellbeing Read Sections Managing Psoriatic Arthritis Handbook Sections How is psoriatic arthritis treated? Non-pharmacological treatments Self-care and lifestyle Read Sections Intimacy, Reproductive Health and Family Life Handbook Sections Relationships and sex Fertility, pregnancy, and breastfeeding Read Sections Psoriatic Arthritis Handbook Handbook

Learn more about international events for psoriatic arthritis. Choose the event and book the date. Επικείμενο και παρελθόν εκδηλώσεις Athens Digital Health Week 2026 16 Φεβ 2026, 9:00 π.μ. – 20 Φεβ 2026, 4:00 μ.μ. Athens, Athens, Greece Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 7th Plenary meeting 09 Δεκ 2025, 9:00 π.μ. – 10 Δεκ 2025, 4:00 μ.μ. Lisbon, Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία IEEE HealthCom 2025 21 Οκτ 2025, 9:00 π.μ. – 7:30 μ.μ. Abu Dhabi, United Arab Emirates Περισσότερες πληροφορίες Στοιχεία HLTH Event 2025 19 Οκτ 2025, 9:00 π.μ. – 22 Οκτ 2025, 6:00 μ.μ. Las Vegas, Las Vegas, NV, USA Περισσότερες πληροφορίες Στοιχεία GRAPPA Annual Meeting 2025 10 Ιουλ 2025, 11:00 π.μ. – 12 Ιουλ 2025, 8:00 μ.μ. Bogota, Colombia Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 6th Plenary meeting 13 Μαΐ 2025, 11:00 π.μ. – 14 Μαΐ 2025, 5:00 μ.μ. Oxford, UK Περισσότερες πληροφορίες Στοιχεία 7th Polythematic Panhellenic Congress of Autoimmune Diseases, Rheumatology and Clinical Immunology 28 Μαρ 2025, 10:00 π.μ. – 30 Μαρ 2025, 8:00 μ.μ. Portaria, Pelion Περισσότερες πληροφορίες Στοιχεία Health Data Summit 2025 19 Μαρ 2025, 9:00 π.μ. – 20 Μαρ 2025, 7:00 μ.μ. The EGG, Brussels, Belgium Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 5th Plenary Meeting 02 Δεκ 2024, 7:00 π.μ. – 03 Δεκ 2024, 5:00 μ.μ. Athens, Greece Περισσότερες πληροφορίες Στοιχεία DSAI 2024 13 Νοε 2024, 7:00 π.μ. – 15 Νοε 2024, 5:00 μ.μ. Khalifa University, Abu Dhabi, United Arab Emirates (UAE) Περισσότερες πληροφορίες Στοιχεία PhD Open Days 2024 - 10th edition 05 Νοε 2024, 7:00 μ.μ. – 11:00 μ.μ. Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία How to communicate about and disseminate project results under Horizon Europe Cluster 1 ‘Health’ and Horizon 2020 24 Οκτ 2024, 12:00 μ.μ. – 1:00 μ.μ. EEST Webinar Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 2nd Plenary meeting (1) 05 Οκτ 2024, 8:00 π.μ. – 06 Οκτ 2024, 6:00 μ.μ. Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 2nd Plenary meeting (1) 28 Σεπ 2024, 8:00 π.μ. – 11:50 μ.μ. Virtual Περισσότερες πληροφορίες Στοιχεία European Researchers’ Night 27 Σεπ 2024, 8:00 π.μ. – 7:40 μ.μ. Lisbon, Portugal Περισσότερες πληροφορίες Στοιχεία InnoHealth Forum 2024 20 Σεπ 2024, 8:00 π.μ. – 21 Σεπ 2024, 6:00 μ.μ. Larissa, Greece Περισσότερες πληροφορίες Στοιχεία IEEE EMBC 2024 15 Ιουλ 2024, 8:00 π.μ. – 19 Ιουλ 2024, 6:00 μ.μ. Orlando, Florida, USA Περισσότερες πληροφορίες Στοιχεία iPROLEPSIS 4th Plenary meeting 01 Ιουλ 2024, 8:00 π.μ. – 02 Ιουλ 2024, 6:00 μ.μ. Munich, Germany Περισσότερες πληροφορίες Στοιχεία Φόρτωση περισσοτέρων

Σχετικά με τα μέλη της κοινοπραξίας Gail Heritage University of Oxford Position Senior Research Manager What is your role in iPROLEPSIS? UK PDPID coordinating center Manager What are your main activities in the project? UK Study manager What is your motivation? Contribution to clinical research to enhance patient experiences and disease outcomes. Francesca Levi-Schaffer The Hebrew University of Jerusalem, Israel Position Professor What is your role in iPROLEPSIS? Researcher What are your main activities in the project? To try to understand the passage from psoriasis to psoriatic arthritis by evaluating in skin biopsies vascularization, mast cell presence and to correlate this with involved joint vascularization What is your motivation? I would like to discover the connections between skin and joints and find a drug/s that can inhabit this progression Laura Coates Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Position NIHR Research Professor What is your role in iPROLEPSIS? Lead for WP5 (clinical studies) What are your main activities in the project? I oversee all of the clinical studies within the consortium. What is your motivation? I am a rheumatologist who has worked in research in psoriatic arthritis for around 20 years. My interest is in improving outcomes for people living with psoriatic arthritis and I believe that work in this project can help us to predict, monitor and understand the disease better in day to day clinics. Coordination Clinical Experts Data Science Software Development Ethics, Legal and Exploitation Dissemination and Communication